RESEARCH

Ethypharm to acquire Altan Pharma, allowing it to enter the Spanish market and expand its Critical Care portfolio and R&D pipeline.

Ethypharm | June 19, 2021

Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.

On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its current Critical Care franchise.

"Altan Pharma's product portfolio and geographic coverage are highly complementary to those of Ethypharm. We look forward to welcoming Altan Pharma's teams, as we are convinced that together, our product portfolio, our R&D and our industrial expertise, will put us in a stronger position to fulfil our commitment to the patients we serve", said Bertrand Deluard, CEO of Ethypharm. "The Altan Pharma acquisition is an important milestone in Ethypharm's transformation journey. By entering the Spanish market and reinforcing our Critical Care franchise, Ethypharm proves once again its ability to execute on its long-term growth ambition."

"Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma's product portfolio"  said Guillermo Herrera, CEO of Altan Pharma. "Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers."

About Altan Pharma
Altan Pharma is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. Altan is a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.

Altan Pharma currently markets a portfolio of over 40 injectable medications used in pain and anaesthesia, epilepsy, oncology, anti-infectives, cardiovascular, and gynecology and is developing an attractive portfolio of additional products in these areas.

Spotlight

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution. The importance of successfully executing a digital health strategy, as well as creating new financial models and partnerships, cannot be understated. Nevertheless, this revolution is not often witnessed in current practice. While incorporation of digital practices has been slow, the future will move quickly. However, instead of fearing the future, the digital health transformation should have pharmaceutical leaders enthusiastic about the possibilities of the very near future. There are clear opportunities on the horizon, and those pharma organizations and leaders who are prepared for the potential, can soon capitalize on them.

Spotlight

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution. The importance of successfully executing a digital health strategy, as well as creating new financial models and partnerships, cannot be understated. Nevertheless, this revolution is not often witnessed in current practice. While incorporation of digital practices has been slow, the future will move quickly. However, instead of fearing the future, the digital health transformation should have pharmaceutical leaders enthusiastic about the possibilities of the very near future. There are clear opportunities on the horizon, and those pharma organizations and leaders who are prepared for the potential, can soon capitalize on them.

Related News

PHARMA TECH

Tranquilmoney Releases PharmTracker for Independent Pharmacies, Small and Medium Pharmacy Chains

Tranquilmoney | December 28, 2020

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases. Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%. Dr. Karun Philip, Chairman and CEO, says "Drug store claims are moderately little with a normal of $40 from the protection plans. More than 20 years, we built up a framework that consolidated Artificial Intelligence, enormous information stockrooms, and area specialists, that in blend permit us to coordinate each installment to its relating guarantee. Thusly, all non-installments are recognized, and an underpayment of even one penny is identified and can be rebilled." PharmTrackerTM can be utilized as a self-administration programming on the web or as a reevaluated administration. Utilizing Tranquiilmoney's framework will help a Pharmacy gather as much as 99.9% from protection, more than the business standard of about 92.5%. Tranquilmoney expenses start at 45 pennies for every case for at least 3000 cases for each month going down to 2 pennies a case for bigger volumes. Here is the finished value list.

Read More

PHARMACY MARKET

Boston Scientific Announces partnership Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "This exchange will help the BTG Specialty Pharmaceuticals business upgrade its potential as a completely coordinated forte drugs stage," said Anthony Higham, president, BTG, Specialty Pharmaceuticals. "We accept our capacities and portfolio firmly supplement those of SERB, and we anticipate this next section as we keep on emphatically sway the lives of patients and the individuals who care for them." The BTG Specialty Pharmaceuticals business creates, fabricates and markets life-sparing cures utilized in clinics and crisis care settings, including the clinically demonstrated and driving items CroFab®, DigiFab®, and Voraxaze®. The three establishments are required to produce roughly $210 million in income for the entire year 2020. "In the wake of obtaining BTG in 2019 for around $3.7 billion net of money available, and following the end of this exchange, we will have stripped the two BTG non-clinical gadget parcels – Pharmaceutical Licensing sovereignties in the final quarter of 2019 and Specialty Pharmaceuticals declared today – for more than $1.0 billion in net continues," said Jeff Mirviss, chief VP and president, Peripheral Interventions, Boston Scientific. "We keep on being satisfied with the presentation of the center Interventional Medicines business, the essential driver of the BTG securing, which has conveyed solid development and is required to surpass our unique objective of $175 million in collaborations." The arrangement incorporates the exchange of five offices and roughly 280 workers around the world. The exchange is relied upon to shut in the primary portion of 2021, subject to standard administrative endorsements and other shutting conditions.

Read More

BUSINESS INSIGHTS

Karo Pharma acquires OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 2020 on a worldwide premise. The greater part is created in the Nordic business sectors, including Scandinavia, where the brands as of now are dispersed and showcased by Karo under a 7-year permit arrangement that was endorsed in the spring of 2019. The exchange adds around EUR 4m in net deals from new business sectors outside of Scandinavia of which approx. 80% is in Finland. The exchange disentangles the business set-up and gives Karo control of the resources, in this way preparing for long haul advancement of the brands and the worth chain. As far as monetary effect Karo will acknowledge direct investment funds in year 1 of simply under EUR 5m as expenses to Teva are disposed of. Karo as of now popularizes the items in Scandinavia and has dynamic associations with the agreement manufacturers that supply the brands. Subsequently, restricted added expenses and faculty are needed as an immediate aftereffect of the exchange. "The transaction is in full alignment with our strategy of owning and commercializing strong OTC brands within everyday healthcare. It gives us full global control of a very exciting brand portfolio that we will develop and optimize over the next years. It strengthens our position in the Nordic markets and notably it expands our business in Finland where we did not previously control these brands. Over the next years we shall expand life cycle management opportunities, drive activation across more channels and explore geographical market expansion", says Christoffer Lorenzen, CEO of Karo Pharma. The obtaining is an unadulterated resource bargain. No staff or assembling locales are incorporated, which limits business just as the innovation move chances. The exchange, which is financed with existing money and requires no extra credit facilities, is relied upon to close on April 1. About Karo Pharma Karo Pharma delivers smart choices for everyday healthcare. We own and commercialize branded, original over-the-counter products and prescription medicines. Our products are available in more than 60 countries, with Europe and the Nordic region as our core markets. Karo Pharma is headquartered in Stockholm, Sweden and listed on Nasdaq Stockholm Mid Cap.

Read More